203 related articles for article (PubMed ID: 34615996)
21. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
22. Bigelovin triggered apoptosis in colorectal cancer in vitro and in vivo via upregulating death receptor 5 and reactive oxidative species.
Li M; Song LH; Yue GG; Lee JK; Zhao LM; Li L; Zhou X; Tsui SK; Ng SS; Fung KP; Tan NH; Lau CB
Sci Rep; 2017 Feb; 7():42176. PubMed ID: 28181527
[TBL] [Abstract][Full Text] [Related]
23. SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
Roh SA; Kwon YH; Lee JL; Kim SK; Kim JC
Anticancer Res; 2021 Nov; 41(11):5431-5444. PubMed ID: 34732412
[TBL] [Abstract][Full Text] [Related]
24. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
Yue D; Sun X
Cancer Biol Ther; 2019; 20(3):284-294. PubMed ID: 30359552
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer.
Hashimoto M; Masuda T; Nakano Y; Tobo T; Saito H; Koike K; Takahashi J; Abe T; Ando Y; Ozato Y; Hosoda K; Higuchi S; Hisamatsu Y; Toshima T; Yonemura Y; Hata T; Uemura M; Eguchi H; Doki Y; Mori M; Mimori K
Cancer Sci; 2024 Jun; 115(6):1866-1880. PubMed ID: 38494600
[TBL] [Abstract][Full Text] [Related]
28. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
29. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract][Full Text] [Related]
30. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib.
Edagawa M; Kawauchi J; Hirata M; Goshima H; Inoue M; Okamoto T; Murakami A; Maehara Y; Kitajima S
J Biol Chem; 2014 Aug; 289(31):21544-61. PubMed ID: 24939851
[TBL] [Abstract][Full Text] [Related]
31. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
32. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
[TBL] [Abstract][Full Text] [Related]
33. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
34. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
Shivange G; Mondal T; Lyerly E; Bhatnagar S; Landen CN; Reddy S; Kim J; Doan B; Riddle P; Tushir-Singh J
Cell Rep; 2021 Nov; 37(5):109953. PubMed ID: 34731630
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
36. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
37. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
38. Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer.
Zhou Y; Zhang W; Wang B; Wang P; Li D; Cao T; Zhang D; Han H; Bai M; Wang X; Zhao X; Lu Y
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38429070
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
40. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
Zhao X; Yuan C; Wangmo D; Subramanian S
Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
